"Tempus AI" for Smart Diagnosis is on the way to raise $ 410 million in a preliminary public offer

Tempus AI Inc., a technology platform that uses artificial intelligence to process medical data, put its share in its subscription to the highest level in the price range to raise $ 410.7 million. ‘Timbus AI’ joined a group of companies offering their public subscription shares while promoting their dependence on artificial intelligence, as it sold $ 37 per share for $ 37 per share, after offering it for $ 35, according to a statement issued on Thursday, which was published by a previous report. According to the price announced in the public subscription, the market value of the company will reach $ 6.1 billion on the basis of the existing shares listed in the deposit -referral with the US Security and Bursary Committee. The largest investor of the company describes the company “Timbus AI”, which was founded in Chicago, which was founded in 2015, is the job as ‘smart diagnoses’ for exact medicine. The company’s platform connects the results of the laboratory with the patient’s clinical data, and it was used by more than 7,000 doctors in hundreds of service providers according to the records. The company has a team that includes about 2300 employees, of which about 250 have medical certificates or postgraduate studies. ‘Timbus AI’ entered into a $ 214 million net loss of $ 532 million in 2023, compared to a net loss of $ 290 million in revenue of $ 321 million in the previous year, according to deposit newspapers. Among the largest investors of the company, Erik Livkovsky, founder and CEO, as well as a company controlled by ‘Kimberly Kili’, and Baillie Gifford & Coentities. The company has a double stock structure that ‘Levkovsky’ gives 65% of the right to vote after the public subscription. The presentation process is led by Morgan Stanley, “GB Morgan” and “Allen & Co”. The company’s shares are expected to start today, Friday, in the “Nasdaq Global Select Market”.